TNB-383B
- Generic Name
- TNB-383B
- Drug Type
- Biotech
- Background
TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06896916
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 440
- Registration Number
- NCT06892522
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT06158841
- Locations
- 🇺🇸
University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona, United States
🇺🇸Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05650632
- Locations
- 🇫🇷
HCL - Hopital Lyon Sud /ID# 251223, Pierre Benite CEDEX, Rhone, France
🇺🇸Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona, United States
🇺🇸Highlands Oncology Group - Springdale /ID# 267742, Springdale, Arkansas, United States
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT05286229
- Locations
- 🇯🇵
Kanazawa University Hospital /ID# 240948, Kanazawa-shi, Ishikawa, Japan
🇯🇵Okayama Medical Center /ID# 240949, Okayama-shi, Okayama, Japan
🇯🇵National Cancer Center Hospital East /ID# 240943, Kashiwa-shi, Chiba, Japan
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05259839
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio /ID# 242974, Sevilla, Spain
🇦🇺St George Hospital /ID# 243740, Kogarah, New South Wales, Australia
🇺🇸University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas, United States
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- TeneoOne Inc.
- Registration Number
- NCT04453397
- Locations
- 🇺🇸
Wake Forest, Winston-Salem, North Carolina, United States
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT03933735
- Locations
- 🇺🇸
Mayo Clinic - Rochester /ID# 238683, Rochester, Minnesota, United States
🇺🇸Wisconsin Medical Center /ID# 238684, Milwaukee, Wisconsin, United States
🇺🇸University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.